Competitor Landscape: Sjögren's Syndrome

Competitor Landscape: Sjögren's Syndrome


Competitor Landscape: Sjögren's Syndrome, briefings contain evaluations of ongoing development activities within the Sjogren's (Sjögren) syndrome market, together with analysis of current & potential future product positioning.

Key Highlights from the report -

  • Primary completion date of Phase II RSLV-132 trial changed from October 2018 to July 2018 and status changed from ‘active, not recruiting’ to ‘completed’.
  • Gilead announced that data from the Phase II study in Sjogren’s (Sjögren) syndrome is anticipated in H1 2019.
  • GSK announced that proof-of-concept data for its Phase II belimumab + rituximab trial in Sjogren’s (Sjögren) syndrome is expected in H1 2020.
Competitor Landscape: Sjogren's Syndrome (Sjögren) report includes four key sections.

Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted the Sjogren's (Sjögren) syndrome market landscape.

Landscape Updates: Section contains the following analysis -
  • ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher, and timeline forecasts for each approved product’s lifecycle management initiatives.
Pipeline Landscape: Section contains the following analysis -
  • An overview of pipeline candidates, containing snapshots of current development status.
Appendix: Contains the following information -
  • Current Early Stage Sjogren's (Sjögren) syndrome Pipeline & candidate ‘Watch List’.
  • Timeline Assumptions, including standard assumptions & drug-specific assumptions.
  • The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy
  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Introduction to Sociable Pharma’s ‘Competitor Landscape’
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Pipeline Landscape
Overview: Pipeline Candidates (≥ Phase II)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook